US Patent

US8435502 — Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers

Method of Use · Assigned to Galderma Research and Development SNC · Expires 2026-09-15 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using a composition containing naphthoic acid compounds and polyurethane polymers for treating acne.

USPTO Abstract

Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.

Drugs covered by this patent

Differin (ADAPALENE) · Galderma Labs Lp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1078`	—	Differin

Patent Metadata

Patent number: US8435502
Jurisdiction: US
Classification: Method of Use
Expires: 2026-09-15
Drug substance claim: No
Drug product claim: Yes
Assignee: Galderma Research and Development SNC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.